TOKYO, Jan 29 (Reuters) - Japan's No. 3 drugmaker, Daiichi Sankyo (4568.T), said on Friday its nine-month recurring profit fell 2.7 percent, but it upgraded its outlook citing a recovery at its Indian unit Ranbaxy Laboratories (RANB.BO).
TOKYO, Jan 29 (Reuters) - Japan's No. 3 drugmaker, Daiichi Sankyo (4568.T), said on Friday its nine-month recurring profit fell 2.7 percent, but it upgraded its outlook citing a recovery at its Indian unit Ranbaxy Laboratories (RANB.BO).
